Each film coated tablets contains Linagliptin 5 mg.
As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Linaglip may be used as monotherapy or in combination with other common antidiabetic medications including Metformin, Sulfonylurea, Pioglitazone, or Insulin.
As a replacement therapy it is suitable when Metformin therapy is not appropriate due to intolerance or do not provide adequate glycemic control as monotherapy or other antidiabetic drugs are to be discontinued due to renal or hepatic impairment.
The recommended dose of Linagliptin is 5 mg once daily and can be taken with or without food. If added with Metformin, the dose of Metformin should be maintained and Linaglip administered concomitantly. When used in combination with Sulfonylurea, a lower dose of Sulfonylurea, a lower dose of Sulfonylurea, a lower dose of Sulfonylurea may be considered to reduce the risk of hypoglycemia.
Linaglip is contraindicated to patients hypersensitive to Linagliptin or any of the excipients.
Should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.
Renal or hepatic impairment: No dose adjustment required.
Use in Pregnancy: There are no adequate and well-controlled studies in pregnant woman. Linagliptin tablets should be used during pregnancy only if the potential benefit of mother justifies the potential risk of the fetus.
Use in Lactation: Caution should be exercised when Linagliptin is administered to a nursing woman.
Use in Children: Safety and effectiveness of Linagliptin in patients below the age of 18 have not been established.
Use in Pregnancy: There are no adequate and well-controlled studies in pregnant woman. Linagliptin tablets should be used during pregnancy only if the potential benefit of mother justifies the potential risk of the fetus.
Use in Lactation: Caution should be exercised when Linagliptin is administered to a nursing woman.
Linagliptin doesn't interact with Metformin, Glyburide, Simvastatin, Warfarin, Digoxin or oral contraceptives. Linagliptin is a weak competitive and a weak to moderate mechanism-based inhibitor of VYP isozyme CYP3A4, but does not inhibit other CYP isozymes. Again it doesn't act as an inducer of CYP isozymes.
A10BH05 - linagliptin ; Belongs to the class of dipeptidyl peptidase 4 (DPP-4) inhibitors. Used in the treatment of diabetes.
Sign Out
